| A | B | C | D | E | F | G | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | AA | AB | AC | AD | AE | AF | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Company | Federal Agency or Agencies | Contract Number | Date (M/D/Y) | Amount | Purpose | URL | practical application definition changes | Standard march-in (y/n) | march-in changes | 52.227-1 or other consent to use patented inventions | 52.227-3 or other patent infrigement indemnity | 52.22705, waiver of indemity | Comments on rights in data | ||||||||||||||
2 | 60 Degrees Pharmaceuticals | DOD/Army | W911QY2190011 | 12/4/2020 | $4,999,814 | Therapeutic | https://archive.org/download/dod-60-degrees-pharmaceuticals-contract-w911qy2190011/DOD-60%20Degrees%20Pharmaceuticals%20Contract-W911QY2190011-4Dec2020.pdf | 52.227-1 Authorizes and consents except for products commercially available by Recipient | Patent indemnity. T | |||||||||||||||||||
3 | 98Point6 | HHS/ASPR/BARDA | 75A50120C00151 | 10/9/2020 | $700,000 | COVID-19 Smartphone Technology | https://www.keionline.org/misc-docs/FOIA/HHS-98POINT6-Contract-75A50120C001519-9Oct2020.pdf | N/A | Unknown | Unknown | 52.227-1 | 52.227-3 | Any data delivered under this contract is subject to the Rights in Data- General clause 52.227-14 included in this contract | |||||||||||||||
12 | Altimmune, Inc. | |||||||||||||||||||||||||||
13 | ANP Technologies, Inc. | DOD/Army | W911QY20D0019 | 5/29/2020 | $60,100,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/DoD-ANP-Technologies-Contract-W911QY20D0019-29May2020.pdf | N/A | Y | N/A | 52.227-1 | no | DFARS 252.227-7013 Rights in Technical Data -- Noncommercial Items | |||||||||||||||
14 | ANP Technologies, Inc. | DOD/Army | W911QY20D0019/Task Order W911QY20F0269 | 6/2/2020 | $110,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/DOD-ANP-Technologies-Contract-W911QY20D0019-2Jun2020.pdf | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
16 | ANP Technologies, Inc. | DOD/Army | W911QY20D0019-P00002 | 7/1/2020 | $60,110,192 | Diagnostic | URL (Page 33) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
17 | ANP Technologies, Inc. | DOD/Army | W911QY20D0019-P00003 | 7/21/2020 | Redacted | Diagnostic | URL (Page 37) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
32 | AstraZeneca | DOD/Army | W911QY20C0119 | 9/30/2020 | Redacted | Therapeutic | https://www.keionline.org/misc-docs/DoD-AstraZeneca-Contract-W911QY20C0119-30Sept2020.pdf | N/A | N/A | N/A | 52.227-1 | N/A | ||||||||||||||||
36 | Beckman Coulter Inc | HHS/ASPR/BARDA | 75A50119C00078 | 9/30/2019 | Redacted | Thermometers | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Beckman-Coulter-Contract-75A50119C00078-30Sept2019.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
38 | Beckman Coulter Inc | HHS/ASPR/BARDA | 75A50120C00189 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Beckman-Coulter-Contract-75A50120C00189-28Sept2020.pdf | 52.227-1 | 52.227-3 | |||||||||||||||||||||
77 | ChemBio Diagnostic Systems | HHS/ASPR/BARDA | 75A50120C00138 | Diagnostic | https://archive.org/download/hhs-barda-chembio-contract-75a50120c00138/HHS-BARDA-ChemBio-Contract-75A50120C00138-5July2020.pdf | 52.227-1 | 52.227-3 | |||||||||||||||||||||
79 | Controlant | DOD/Army | W911QX21C0010 | Temperature Monitoring Services | https://www.keionline.org/misc-docs/FOIA/DOD-Controlant-Contract-W911QX21C0010-25Nov2020.pdf | 52.227-1 | no | |||||||||||||||||||||
81 | Corning | DOD/Army | W911NE2030004 | 5/6/2020 | $204,000,000 | Glass tubing and vials/cartridges | https://www.keionline.org/misc-docs/DoD-Corning-Contract-W911NF2030004-5June2020.pdf | Replaces with "capable of being utilized" | Unknown | Unknown | 52.227-1 except for deliverables commercially available to the public by the Recipient. | Government obtains unlimited right in any data generated under the Agreement | ||||||||||||||||
83 | Cue Health | HHS/ASPR/BARDA | HHS0100201800016C | 6/4/2018 | $14,000,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Cue-Health-Contract-HHSO100201800016C-4June2018.pdf | N/A | 52.227-1 | no | Government has limited rights in data | |||||||||||||||||
89 | Cytiva (Global Life Sciences Solutions USA LLC) | DOD/Army | W911NF2130001 | 10/13/2020 | $32,190,000 | Expansion of distribution and development capacities | https://www.keionline.org/misc-docs/FOIA/DoD-Cytiva-GlobalLifeSciencesSolutions-Contract-W911NF2130001-13Oct2020.pdf | N/A | Unknown | Unknown | 52.227-1 | Government only has Limited rights to data generated under this Agreement | ||||||||||||||||
90 | Cytovale | HHS/ASPR/BARDA | 75A50119C00072 | 9/28/2019 | $3,407,480 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Cytovale-Contract-75A50119C00072-28Sept2019.pdf | N/A | Y | N/A | 52.227-1 | Standard, but involves Alt. II of 52.227-14 | ||||||||||||||||
92 | DiaSorin Inc. | HHS/ASPR/BARDA | 75A50120C00070 | 4/10/2020 | $180,045 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-DiaSorin-Contract-75A50120C00017-11Mar2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard data rights: 52.227-14 Rights in Data - General | |||||||||||||||
93 | DiaSorin Inc. | HHS/ASPR/BARDA | 75A50120C00070-P00001 | 7/6/2020 | $291,135 | Diagnostic | https://archive.org/download/hhs-barda-diasorin-contract-75a50120c00070/HHS-BARDA-DiaSorin-Contract-75A50120C00070-P00001-7July2020.pdf | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
95 | DiaSorin Molecular LLC | HHS/ASPR/BARDA | 75A50120C00017 | 3/11/2020 | $697,423 | Diagnostic | https://archive.org/download/hhs-barda-diasorin-contract-75a50120c00017/HHS-BARDA-DiaSorin-Contract-75A50120C00017-11March2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard data rights: 52.227-14 Rights in Data - General | |||||||||||||||
103 | Eli Lilly | DOD/Army | W911QY21C0016 | 10/26/2020 | $1,187,500,000 | Therapeutic | https://www.keionline.org/misc-docs/FOIA/DoD-Eli-Lilly-Contract-W911QY21C0016-27Oct2020.pdf | N/A | N/A | N/A | 52.227-1 | 52.227-3 | 252.227-7015 Technical Data--Commercial Items | |||||||||||||||
104 | Eli Lilly | DOD/Army | W911QY21C0016 P00001 | 11/9/2020 | $375,000,000 | Therapeutic | URL (Page 38) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
105 | Eli Lilly | DOD/Army | W911QY21C0016 P00002 | 11/18/2020 | No change | Therapeutic | URL (Page 44) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
106 | Eli Lilly | DOD/Army | W911QY21C0016 P00003 | 11/19/2020 | No change | Therapeutic | URL (Page 48) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
107 | Eli Lilly | DOD/Army | W911QY21C0016 P00004 | 11/25/2020 | $812,500,000 | Therapeutic | URL (Page 51) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
108 | Eli Lilly | DOD/Army | W911QY21C0016 P00005 | 12/2/2020 | $1,187,500,000 | Therapeutic | URL (Page 54) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
113 | Emergent Biosolutions | HHS/ASPR/BARDA | HHSO1002012000041 | 6/15/2012 | $99,941,720 | Vaccine Manufacture | https://www.keionline.org/misc-docs/HHS-BARDA-Emergent-Contract-HHSO100201200004I-15June2012.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard data rights: 52.227-14 Rights in Data - General | |||||||||||||||
114 | Emergent Biosolutions | HHS/ASPR/BARDA | HHSO1002012000041 task order 75A50120F33007 | 5/24/2020 | $628,250,000 | Vaccine Manufacture | https://www.keionline.org/misc-docs/HHS-BARDA-Emergent-SupplyOrder-Contract-HHSO100201200004I-24May2020.pdf | 52.227-1 | ||||||||||||||||||||
119 | EMERGENT MANUFACTURING OPERATIONS BALTIMORE | HHS/ASPR/BARDA | HHSO100201200004I | 6/15/2012 | https://www.keionline.org/misc-docs/HHS-BARDA-Emergent-Contract-HHSO100201200004I-15June2012.pdf | 52.227-1 | ||||||||||||||||||||||
120 | EMERGENT MANUFACTURING OPERATIONS BALTIMORE | HHS/ASPR/BARDA | HHSO100201200004I - Supply Order | 5/24/2020 | https://www.keionline.org/misc-docs/HHS-BARDA-Emergent-SupplyOrder-Contract-HHSO100201200004I-24May2020.pdf | 52.227-1 | ||||||||||||||||||||||
121 | EMERGENT MANUFACTURING OPERATIONS BALTIMORE | HHS/ASPR/BARDA | HHSO100201200004I - Supply Order | 7/23/2020 | https://www.keionline.org/misc-docs/HHS-BARDA-Emergent-SupplyOrder-Contract-HHSO100201200004I-23July2020.pdf | 52.227-1 | ||||||||||||||||||||||
134 | Empatica Inc. | HHS/ASPR/BARDA | 75A50120C00132 | 6/18/2020 | $717,807 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Empatica-Contract-75A50120C00132-18June2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
137 | Esperovax | HHS/ASPR/BARDA | 75A50120C00154 | 7/26/2020 | $606,780 | Oral Vaccine Administration | https://archive.org/download/hhs-barda-esperovax-contract-75a50120c00154/HHS-BARDA-Esperovax-Contract-75A50120C00154-NotDated.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
138 | Evidation Health Inc. | HHS/ASPR/BARDA | 75A50120C00091 | 4/17/2020 | $720,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Evidation-Health-Contract-75A50120C00091-17April2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
153 | Genmark Diagnostics, Inc. | HHS/ASPR/BARDA | 75A50120C00022 | 3/20/2020 | $749,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-GenMark-Diagnostics-Contract-75A50120C00022-20Mar2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
155 | Genmark Diagnostics, Inc. | HHS/ASPR/BARDA | 75A50120C00022-P00002 | 7/20/2020 | No change | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-GenMark-Diagnostics-Contract-75A50120C00022-P00002-20July2020.pdf | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
215 | Hememics Biotechnologies Inc. | HHS/ASPR/BARDA | 75A50120C00074 | 4/9/2020 | $638,000 | Diagnostic | https://archive.org/download/hhs-barda-hememics-contract-75a50120c00074/HHS-BARDA-Hememics-Contract-75A50120C00074-9April2020.pdf | No difference | Y | No difference | 52.227-1 | 52.227-3 | FAR 52.227-14 | |||||||||||||||
216 | Hememics Biotechnologies Inc. | HHS/ASPR/BARDA | 75A50120C00074-P00001 | 6/3/2020 | $25,000 | Diagnostic | https://archive.org/download/hhs-barda-hememics-contract-75a50120c00074/HHS-BARDA-Hememics-Contract-75A50120C00074-P00001-3June2020.pdf | No difference | Y | No difference | 52.227-1 | no change | FAR 52.227-14 | |||||||||||||||
218 | Hologic, Inc. | HHS/ASPR/BARDA | 75A50120P00100 | 8/7/2020 | $8,912,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Hologic-Contract-75A50120P00100-7Aug2020.pdf | Could not locate | Could not locate | Could not locate | 52.227-1 | Could not locate | ||||||||||||||||
220 | Hologic, Inc. | HHS/ASPR/BARDA | 75A50120C00015 | Diagnostic | https://archive.org/download/hhs-barda-hologic-order-75a50120c000156/HHS-BARDA-Hologic-Order-75A50120C00015-6March2020.pdf | 52.227-1 | 52.227-3 | |||||||||||||||||||||
226 | Immunexpress | HHS/ASPR/BARDA | 75A50120C00125 | 6/11/2020 | $599,549 | Diagnostic | https://archive.org/download/hhs-barda-immunexpress-contract-75a50120c00125/HHS-BARDA-ImmunExpress-Contract-75A50120C00125-11June2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
228 | Inbios International | ASPR/BARDA | 75A50120C0090C | 4/26/2020 | $594,943 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-InBios-Contract-75A50120C00090-26April2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
252 | Johns Hopkins Univeristy | DOD/Army/Natick | W911QY-20-9-0012 | 6/8/2020 | Redacted | Therapeutic | https://www.keionline.org/misc-docs/FOIA/DOD-Johns-Hopkins-OTA-Contract-W911QY2090012-8June2020.pdf | Not included | Not included | Not included | 52.227-1 except for deliverables commercially available to the public by the Awardee | Weaker compared to the DFARS. Limited to use of data within the government. | ||||||||||||||||
266 | Luminex Corporation | HHS/ASPR/BARDA | 75A50120C00043 | 9/23/2020 | $683,500 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Luminex-Contract-75A50120C00043-27March2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | FAR 52.227-14 | |||||||||||||||
267 | Luminex Corporation | HHS/ASPR/BARDA | 75A50120C00037 | 3/26/2020 | $642,450 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Luminex-Contract-75A5012C00037-26March2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | FAR 52.227-14 | |||||||||||||||
268 | Luminex Corporation | HHS/ASPR/BARDA | 75A50120C00179 | 9/23/2020 | $683, 500 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Luminex-Contract-75A50120C00179-23Sept2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | FAR 52.227-14 | |||||||||||||||
269 | Maxim Biomedical, Inc. | DOD/Army | W911QY20F0244/W911QY20D0018 | 5/11/2020 | $45,100,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/DoD-Maxim-Contract-W911QY20D0018-11May2020.pdf | N/A | Y | N/A | 52.227-1 | no | DFARS 252.227-7013 (Rights in Technical Data - Noncommercial Items) | |||||||||||||||
270 | Maxim Biomedical, Inc. | DOD/Army | W911QY20F0244/W911QY20D0018-P00001 | 5/19/2020 | $45,107,035 | Diagnostic | URL (Page 30) | No change | No change | No change | 52.227-1 | Adds to Contract Data Requirement List | ||||||||||||||||
271 | Maxim Biomedical, Inc. | DOD/Army | W911QY20F0244/W911QY20D0018-P00002 | 6/1/2020 | $45,518,335 | Diagnostic | URL (Page 43) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
272 | Maxim Biomedical, Inc. | DOD/Army | W911QY20F0244/W911QY20D0018-P00003 | 6/22/2020 | $45,522,085 | Diagnostic | URL (Page 50) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
273 | Maxim Biomedical, Inc. | DOD/Army | W911QY20F0244/W911QY20D0018-P00004 | 7/15/2020 | $45,484,585 | Diagnostic | URL (Page 55) | No change | No change | No change | 52.227-1 | No change | ||||||||||||||||
274 | Mbio Diagnostics | HHS/ASPR/BARDA | 75A50120C00130 | 6/17/2020 | $629,595 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-MBio-Diagnostics-Contract-75A50120C00130-17June2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
279 | Merck Sharp & Dohme | HHS/ASPR/BARDA | HHSO100201600031C | 9/29/16 | Redacted | Vaccine | https://www.keionline.org/misc-docs/FOIA/HHS-Bioprotection-Systems-Corporation-Contract-HHSO100201600031C-29Sept2016.pdf | N/A | Y | N/A | 52.227-1 | no | FAR 52.227-14 | . S/A | ||||||||||||||
286 | Mesa Tech International | HHS/ASPR/BARDA | 75A50120C00019 | 3/13/2020 | Redacted | Diagnostic | https://archive.org/download/hhs-barda-mesa-tech-contract-75a50120c00019/HHS-BARDA-Mesa-Tech-Contract-75A50120C00019-13March2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (FAR 52.227-14) | |||||||||||||||
289 | Moderna | HHS/ASPR/BARDA | 75A50120C00034 | 4/16/2020 | Redacted | Vaccine | https://www.keionline.org/misc-docs/FOIA/BARDA-ModernaTX-Contract-75A50120C00034-16Apr2020.pdf | N/A | Y | N/A | 52.227-1 | no | Certain data developed at private expense, which are redacted, are subject to FAR 52.227-14, Alternate II. Limited rights in data developed exclusively with private funds, even if a deliverable. Under the standard (non-alternate) FAR clause, the government obtains unlimited rights in data delivered under the contract even if developed exclusively with private funds. Page 15 states that data generated before or outside the scope of the agreement are also limited rights data, but that the government will otherwise obtain unlimited rights data delivered under the contract consistent with FAR Clause 52.227-14 (the standard clause). Thus, with limited exceptions, this contract is subject to standard DATA rights. | |||||||||||||||
291 | Moderna | HHS/ASPR/BARDA | HHS0100201600029C | 9/1/2016 | $8,205,759 | Vaccine (ZIKA) | https://www.keionline.org/misc-docs/HHS-BARDA-Moderna-Zika-Contract-HHSO100201600029C-1Sept2016.pdf | N/A | Unknown | Unknown | 52.227-1 | no | Limiteed Data Rights | |||||||||||||||
292 | Moderna | HHS/ASPR/BARDA; DOD/Army/JPEO-CBRND/DCMA | W911QY20C0100 | 8/9/2020 | $1.5 billion | Vaccine | https://www.keionline.org/misc-docs/DOD-Moderna-Contract-W911QY20C0100-9Aug2020-SEC.pdf | N/A | Y | N/A | 52.227-1 | no | DFARS 252.227-7013 | |||||||||||||||
303 | Murtech, Inc. | DOD/Army | W911QY20D0017 | 5/11/2020 | $48,870,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/DoD-Murtech-Contract-W911QY20D0017-11May2020.pdf | N/A | Y | N/A | 52.227-1 | DFARS 252.227-7013 | ||||||||||||||||
304 | Murtech, Inc. | DOD/Army | W911QY20D0017-P00001 | 6/3/2020 | $49,364,708.61. | Diagnostic | URL (Page 32) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
305 | Murtech, Inc. | DOD/Army | W911QY20D0017-P00002 | 6/24/2020 | Redacted | Diagnostic | URL (Page 38) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
306 | Nanomix | HHS/ASPR/BARDA | 75A50120C00060 | 4/2/2020 | $569,647 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Nanomix-Contract-75A50120C00060-2April2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | FAR 52.227-14 | |||||||||||||||
310 | Novavax | DOD/Army | W911QY20C0077 | 6/4/2020 | $60,000,000 | Vaccine | https://www.keionline.org/misc-docs/DOD-Novavax-Contract-W911QY20C0077-4June2020.pdf | N/A | N | Unknown | 52.227-1 | 52.227-3 | Unknown | |||||||||||||||
311 | Novavax | DOD/Army | W911QY20C0077 P0001 | 6/4/2020 | $60,000,000 | Vaccine | https://www.keionline.org/misc-docs/FOIA/DOD-Novavax-Contract-W911QY20C0077-P00001-4June2020.pdf | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
312 | Novavax | DOD/Army | W911QY20C0077 P0002 | 6/4/2020 | $60,000,000 | Vaccine | URL (Page 21) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
313 | Novavax | DOD/Army | W911QY20C0077 P0003 | 6/4/2020 | $45,670,659 | Vaccine | URL (Page 42) | Not amended | Not amended | Not amended | 52.227-1 | 252.227-7015 Technical Data -- Commercial Items | ||||||||||||||||
317 | NOWDiagnostics | HHS/ASPR/BARDA | 75A50120C00156 | 8/27/2020 | $695,500 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-NOWDiagnostics-Contract-75A50120C00156-27Aug2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard: FAR 52.227-14 | |||||||||||||||
323 | Ophirex | USA Med Research Acq Activity | W81XWH20C0066 | 6/19/2020 | $9,873,778 | Therapeutic | https://www.keionline.org/misc-docs/FOIA/DoD-Ophirex-Contract-W81XWH20C0066-19Jun2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | DFARS clause 252.227-7018. | |||||||||||||||
324 | Ophirex | USA Med Research Acq Activity | W81XWH20C0066 P00001 | 6/24/2020 | No change | Therapeutic | URL (Page 55) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
325 | Ophirex | USA Med Research Acq Activity | W81XWH20C0066 P00002 | 8/4/2020 | No change | Therapeutic | URL (Page 58) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
326 | Ophirex | USA Med Research Acq Activity | W81XWH20C0066 P00003 | 12/4/2020 | No change | Therapeutic | URL (Page 60) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
327 | Orasure Technologies Inc. | HHS/ASPR/BARDA | 75A50120C00061 | Not disclosed | $710,310 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Orasure-Contract-75A50120C00061.pdf | No difference | Y | No difference | 52.227-1 | 52.227-3 | FAR Clause 52.227-14 (Rights in Data - General) | |||||||||||||||
328 | Orasure Technologies Inc. | HHS/ASPR/BARDA | 75A50120C00122 | 5/27/2020 | $629,217 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Orasure-Contract-75A50120C00122-27May2020.pdf | No difference | Y | No difference | 52.227-1 | 52.227-3 | FAR Clause 52.227-14 (Rights in Data - General) | |||||||||||||||
329 | Ortho Clinical | HHS/ASPR/BARDA | 75A50120C00123 | 6/12/2020 | $678,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Ortho-Clinical-Contract-75A50120C00123-12June2020-FOIA.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (incorporated by FAR clause) | |||||||||||||||
341 | Philips North America | HHS/BARDA | 75A50120C00097 | 5/7/2020 | $34,893,033 | Ultrasound | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Philips-Contract-75A50120C00097-7May2020.pdf | No difference | Y | No difference | 52.227-1 | 52.227-1 | FAR 52.227-14 and Alt. II (some limited data rights) | |||||||||||||||
343 | Phlow Corp. | HHS/ASPR/BARDA | 75A50120000092 | 5/18/2020 | $354,256,000 | Therapeutic | https://www.keionline.org/misc-docs/HHS-BARDA-Phlow-Contract-75A5012C00092-18May2020.pdf | N/A | Unknown | Unknown | 52.227-1 | Unlimited Data Rights | ||||||||||||||||
345 | Protein Sciences Corporation (Sanofi) | HHS/ASPR/BARDA | HHSO100201600005I-75A50120F33009 | 2/14/2020 | $30,000,000 | Vaccine | https://archive.org/download/hhs-barda-protein-sciences-contract-hhso100201600005i/HHS-BARDA-Protein-Sciences-Contract-HHSO100201600005I-Order-75A50120F33009-14Feb2020.pdf | Unknown | Unknown | Unknown | 52.227-1 | Unknown | ||||||||||||||||
347 | Protein Sciences Corporation (Sanofi) | HHS/ASPR/BARDA | HHSO100201600005I | 8/16/2016 | Could not locate | Vaccine | https://archive.org/download/hhs-barda-protein-sciences-contract-hhso100201600005i/HHS-BARDA-Protein-Sciences-Contract-HHSO100201600005I-16Aug2016.pdf | Could not locate | Could not locate | Could not locate | 52.227-1 | N/A - Could not locate | ||||||||||||||||
358 | Quidel Corporation | HHS/ASPR/BARDA | 75A501200110 | 5/29/2020 | $634,644 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Quidel-Contract-75A50120C00110-29May2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard: FAR 52.227-14 | |||||||||||||||
369 | Retractable Technologies, Inc. (RTI) | DOD/Army | W911SR2030004 | 7/1/2020 | $53,554,286 | Needles & Syringes | https://www.keionline.org/misc-docs/OWS-HHS-RTI-NeedleProduction-Contract-W911SR2030004.pdf | N/A | N | N/A -- not included. | 52.227-1 except for deliverables commercially available to the public by the Recipient | Possibly weaker than the DFARS. Instead of obtaining unlimited rights in data developed exclusively with government funds, the government obtains the right to use the data, but the contract does not state that these rights are unlimited or that the government may authorize others to use the data (as would be the case for unlimited rights). | ||||||||||||||||
378 | Sepsis Alliance | HHS/ASPR/BARDA | HHSO100201900021C | 1/29/2019 | $427,248 | Sepsis Education | https://www.keionline.org/misc-docs/FOIA/HHS-Sepsis-Alliance-Contract-HHSO100201900021C-19Jan2019.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard | |||||||||||||||
385 | SIO2 Medical Products | DOD/Army | W911NF2030003 | 6/5/2020 | Vials | https://www.keionline.org/misc-docs/FOIA/DOD-SIO2-Medical-Contract-W911NF2030003-5June2020.pdf | 52.227-1 Authorizes and consents except for products commercially available by Recipient | |||||||||||||||||||||
386 | Sonica | HHS/ASPR/BARDA | 75A50119C00043 | 8/1/2019 | $656,420 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Sonica-Contract-75A50119C00043-1Aug2019.pdf | No difference | Y | No difference | 52.227-1 | 52.227-3 | 52.227-14 | |||||||||||||||
397 | Tangen Biosciences, Inc. | HHS/ASPR/BARDA | 75A50120C00085 | 4/15/2020 | $696,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/HHS-Tangen-Biosciences-Contract-75A50120C00085-15April2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard | |||||||||||||||
404 | University of Connecticut | HHS/ASPR/BARDA | 75A50120C00162 | 08/18/2020 | $432,990 | Vaccine Microneedle Patch | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-UConn-Contract-75A50120C00162-16Aug2020.pdf | N/A | Y | N/A | 52.227-1 | no | 52.227-14 Alternate IV | |||||||||||||||
405 | Vaxess | HHS/ASPR/BARDA | 75A50120C00160 | 08/06/2020 | $749,000 | Spike Protein Manufacturing | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-Vaxess-Technologies-Contract-75A50120C00160-6Aug2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
410 | Velocity DX | DOD/Army | W911QY20D0031 | 08/12/2020 | $67,200,000 | Diagnostic | https://www.keionline.org/misc-docs/FOIA/DoD-VelocityDX-Contract-W911QY20D0031-12Aug2020.pdf | N/A | Y | N/A | 52.227-1 | no | 252.227-7013, 252.227-7013, & other clauses. | |||||||||||||||
411 | Verndari, Inc. | HHS/ASPR/BARDA | 75A50120C00153 | 07/03/2XXX [Redacted in Part] | $698,215 | Spike Protein Delivery Technology | https://archive.org/download/hhs-barda-verndari-75a50120c0015324/HHS-BARDA-Verndari-75A50120C00153-24July2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
416 | Vital Connect Inc. | HHS/ASPR/BARDA | 75A50120C00108 | 05/20/2020 | $592,791 | Algorithm Optimization | https://www.keionline.org/misc-docs/FOIA/HHS-BARDA-VitalConnect-Contract-75A50120C00108-20May2020.pdf | N/A | Y | N/A | 52.227-1 | 52.227-3 | Standard (52.227-14) | |||||||||||||||
425 | Worlds Enterprises | DOD/Army | W911SR21C0008 | 11/13/2020 | $402,350 | Screening devices | https://www.keionline.org/misc-docs/FOIA/DOD-World-Enterprises-W911SR21C0008-13Nov2020.pdf | Not included | Not included | Not included | 52.227-1 | no | Government purpose rights | |||||||||||||||
426 | Worlds Enterprises | DOD/Army | W911SR21C0008-P00001 | 12/9/2020 | No change | Screening devices | URL (Page 33) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
427 | Worlds Enterprises | DOD/Army | W911SR21C0008-P00002 | 1/20/2021 | No change | Screening devices | URL (Page 46) | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
428 | Worlds Enterprises | DOD/Army | W911SR21C0008-P00003 | 5/27/2021 | No change | Screening devices | https://www.keionline.org/misc-docs/FOIA/DOD-World-Enterprises-W911SR21C0008-13Nov2020.pdf | Not amended | Not amended | Not amended | 52.227-1 | Not amended | ||||||||||||||||
429 | ||||||||||||||||||||||||||||
430 | ||||||||||||||||||||||||||||
431 | ||||||||||||||||||||||||||||
432 | ||||||||||||||||||||||||||||
433 | ||||||||||||||||||||||||||||
434 | ||||||||||||||||||||||||||||
435 | ||||||||||||||||||||||||||||
436 |